Increased production of amyloid β-peptide (Aβ) and altered processing of tau in Alzheimer's disease (AD) are associated with synaptic dysfunction, neuronal death and cognitive and behavioural deficits. Neuroinflammation is also a prominent feature of AD brain and considerable evidence indicates that inflammatory events play a significant role in modulating the progression of AD. The role of microglia in AD inflammation has long been acknowledged. Substantial evidence now demonstrates that astrocyte-mediated inflammatory responses also influence pathology development, synapse health and neurodegeneration in AD. Several anti-inflammatory therapies targeting astrocytes show significant benefit in models of disease, particularly with respect to tau-associated neurodegeneration. However, the effectiveness of these approaches is complex, since modulating inflammatory pathways often has opposing effects on the development of tau and amyloid pathology, and is dependent on the precise phenotype and activities of astrocytes in different cellular environments. An increased understanding of interactions between astrocytes and neurons under different conditions is required for the development of safe and effective astrocyte-based therapies for AD and related neurodegenerative diseases.
Astrocytes and neuroinflammation in Alzheimer's disease
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Emma C. Phillips, Cara L. Croft, Ksenia Kurbatskaya, Michael J. O’Neill, Michael L. Hutton, Diane P. Hanger, Claire J. Garwood, Wendy Noble; Astrocytes and neuroinflammation in Alzheimer's disease. Biochem Soc Trans 1 October 2014; 42 (5): 1321–1325. doi: https://doi.org/10.1042/BST20140155
Download citation file: